4.6 Article

miR-9-5p Exerts a Dual Role in Cervical Cancer and Targets Transcription Factor TWIST1

期刊

CELLS
卷 9, 期 1, 页码 -

出版社

MDPI
DOI: 10.3390/cells9010065

关键词

cervical cancer; HPV; miR-9-5p; methylation; TWIST1

资金

  1. Dutch Cancer Society [KWF2012-5708]
  2. European Research Council (ERC) [322986]

向作者/读者索取更多资源

Squamous cell carcinoma (SCC) and adenocarcinoma (AC) represent the major cervical cancer histotypes. Both histotypes are caused by infection with high-risk HPV (hrHPV) and are associated with deregulated microRNA expression. Histotype-dependent expression has been observed for miR-9-5p, showing increased expression in SCC and low expression in AC. Here, we studied the regulation and functionality of miR-9-5p in cervical SCCs and ACs using cervical tissue samples and hrHPV-containing cell lines. Expression and methylation analysis of cervical tissues revealed that low levels of miR-9-5p in ACs are linked to methylation of its precursor genes, particularly miR-9-1. Stratification of tissue samples and hrHPV-containing cell lines suggested that miR-9-5p depends on both histotype and hrHPV type, with higher expression in SCCs and HPV16-positive cells. MiR-9-5p promoted cell viability and anchorage independence in cervical cancer cell lines SiHa (SCC, HPV16) and CaSki (metastasized SCC, HPV16), while it played a tumor suppressive role in HeLa (AC, HPV18). TWIST1, a transcription factor involved in epithelial-to-mesenchymal transition (EMT), was established as a novel miR-9-5p target. Our results show that miR-9-5p plays a dual role in cervical cancer in a histotype- and hrHPV type-dependent manner. MiR-9-5p mediated silencing of TWIST1 suggests two distinct mechanisms towards EMT in cervical cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Functional Screen for microRNAs Suppressing Anchorage-Independent Growth in Human Cervical Cancer Cells

Angelina Huseinovic, Annelieke Jaspers, Annina P. van Splunter, Hanne Sorgard, Saskia M. Wilting, Dorian R. A. Swarts, Ida H. van der Meulen, Victor W. van Beusechem, Renee X. de Menezes, Renske D. M. Steenbergen

Summary: The progression of anchorage-dependent epithelial cells to anchorage-independent growth is a critical feature of malignant transformation. In this study, the researchers used an in vitro model of HPV-induced transformation to investigate the role of microRNAs in anchorage-independent growth. They developed alternative functional screening methods using ultra-low attachment plates and identified a set of microRNAs that consistently suppressed growth. These microRNAs may serve as specific biomarkers for detecting and treating HPV-induced precancerous lesions progressing to invasive cancer.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Circulating tumour cells are associated with histopathological growth patterns of colorectal cancer liver metastases

Y. M. Meyer, S. M. Wilting, J. Kraan, P. Olthof, P. Vermeulen, J. Martens, D. J. Grunhagen, S. Sleijfer, C. Verhoef

Summary: This study examined the association between preoperative measurement of Circulating Tumour Cells (CTCs) and Histopathological Growth Patterns (HGPs) in patients with Colorectal Liver Metastases (CRLM). The results showed that the preoperative absence of CTCs was associated with desmoplastic HGP (dHGP) in chemo naive CRLM patients without extrahepatic disease. The integration of CTC count in multivariable prediction models may aid in the preoperative identification of HGPs of CRLM.

CLINICAL & EXPERIMENTAL METASTASIS (2022)

Review Oncology

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses

Jan M. Van Rees, Lissa Wullaert, Alexander A. J. Grueter, Yassmina Derraze, Pieter J. Tanis, Henk M. W. Verheul, John W. M. Martens, Saskia M. Wilting, Geraldine Vink, Jeroen L. A. Van Vugt, Nick Beije, Cornelis Verhoef

Summary: This systematic review and meta-analyses demonstrate a strong association between ctDNA and recurrent disease in non-metastatic rectal cancer. ctDNA analysis can stratify patients into high and low risk groups for recurrence, especially when detected after neoadjuvant treatment and surgery. Future research should focus on the feasibility of ctDNA-guided treatment and follow-up strategies in rectal cancer.

FRONTIERS IN ONCOLOGY (2023)

Article Oncology

mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer

Khrystany T. Isebia, Bianca Mostert, Teoman Deger, Jaco Kraan, Vanja de Weerd, Esther Oomen-de Hoop, Paul Hamberg, Brigitte C. M. Haberkorn, Helgi H. Helgason, Ronald de Wit, Ron H. J. Mathijssen, Martijn P. Lolkema, Saskia M. Wilting, Job van Riet, John W. M. Martens

Summary: In this study, the researchers found that the abnormal aneuploidy score of cell-free tumor DNA (ctDNA) in the blood can predict the survival of metastatic castration-resistant prostate cancer (mCRPC) patients, making it a potential biomarker.

MOLECULAR ONCOLOGY (2023)

Article Oncology

Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting

Manouk K. Bos, Sarah R. Verhoeff, Sjoukje F. Oosting, Willemien C. van der Houven van Oordt, Ruben G. Boers, Joachim B. Boers, Joost Gribnau, John W. M. Martens, Stefan Sleijfer, Carla M. L. van Herpen, Saskia M. Wilting

Summary: For patients with intermediate risk renal cell carcinoma, some have a slow disease progression. Delaying treatment for metastatic disease by entering a watchful waiting period is a safe option for these patients. However, it is currently difficult to identify patients with indolent disease or those with rapidly progressive disease. This study investigates the use of cell-free DNA (cfDNA) as a blood-based biomarker to identify patients with rapid disease progression.

CANCERS (2023)

Article Oncology

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients? Needs?

Elisabeth M. Jongbloed, Hedwig M. Blommestein, Hannah M. van Schoubroeck, John W. M. Martens, Saskia M. Wilting, Carin A. Uyl-de Groot, Agnes Jager

Summary: The addition of two years of abemaciclib treatment to high-risk ER+, HER2-early breast cancer patients has been approved by the FDA. Using detection of minimal residual disease (MRD) through patient-informed circulating tumor DNA assays, the addition of abemaciclib treatment shows cost-effectiveness for high-risk patients. However, adding abemaciclib to all high-risk patients is not cost-effective, while MRD-guided treatment is more cost-effective compared to standard treatment.

BREAST CANCER-TARGETS AND THERAPY (2023)

Article Immunology

Detection of dendritic cell subsets in the tumor microenvironment by multiplex immunohistochemistry

Iris A. E. van der Hoorn, Evgenia Martynova, Beatriz Subtil, Jelena Meek, Kiek Verrijp, Johannes Textor, Georgina Florez-Grau, Berber Piet, Michel M. van den Heuvel, I. Jolanda M. de Vries, Mark A. J. Gorris

Summary: This paper describes the development, validation, and quantitative analysis of a multiplex immunohistochemistry panel pipeline with which conventional type 1 dendritic cells (cDC1s), cDC2s, and plasmacytoid DCs can be detected in the spatial context of the tumor microenvironment.

EUROPEAN JOURNAL OF IMMUNOLOGY (2023)

Article Multidisciplinary Sciences

Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels

Elisabeth M. Jongbloed, Maurice P. H. M. Jansen, Vanja de Weerd, Jean A. Helmijr, Corine M. Beaufort, Marcel J. T. Reinders, Ronald van Marion, Wilfred F. J. van IJcken, Gabe S. Sonke, Inge R. Konings, Agnes Jager, John W. M. Martens, Saskia M. Wilting, Stavros Makrodimitris

Summary: Next generation sequencing of cfDNA is a promising method for treatment monitoring and therapy selection in MBC. However, distinguishing tumor-specific variants from sequencing artefacts and germline variation is challenging. To address this, a machine learning model was built to remove false positive variant calls and select tumor-derived variants.

SCIENTIFIC REPORTS (2023)

Article Oncology

Hypermethylation of DNA Methylation Markers in Non-Cirrhotic Hepatocellular Carcinoma

Siyu Fu, Teoman Deger, Ruben G. Boers, Joachim B. Boers, Michael Doukas, Joost Gribnau, Saskia M. Wilting, Jose D. Debes, Andre Boonstra

Summary: In this study, aberrant hypermethylation changes in HOXA1, CLEC11A, AK055957, and TSPYL5 were identified in non-cirrhotic HCC tissues compared to cirrhosis, hepatitis, and benign lesions, providing potential detectable biomarkers for these unusual HCC cases.

CANCERS (2023)

Article Oncology

Liquid Biopsies for Colorectal Cancer and Advanced Adenoma Screening and Surveillance: What to Measure?

Ellis L. Eikenboom, Saskia M. Wilting, Teoman Deger, Malgorzata I. Srebniak, Monique Van Veghel-Plandsoen, Ruben G. Boers, Joachim B. Boers, Wilfred F. J. van IJcken, Joost H. Gribnau, Peggy Atmodimedjo, Hendrikus J. Dubbink, John W. M. Martens, Manon C. W. Spaander, Anja Wagner

Summary: We assessed which ctDNA assay might be most suitable for a ctDNA-based CRC screening/surveillance blood test. The results showed that cfDNA methylation profiles could discriminate all microsatellite instable advanced neoplasia, making it a particularly promising tool for Lynch syndrome surveillance. Larger studies are needed to validate these findings.

CANCERS (2023)

Article Oncology

Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling

Lindsay Angus, Marcel Smid, Saskia M. Wilting, Manouk K. Bos, Neeltje Steeghs, Inge R. H. M. Konings, Vivianne C. G. Tjan-Heijnen, Johanna M. G. H. van Riel, Agnes J. van de Wouw, Edwin Cuppen, Martijn P. Lolkema, Agnes Jager, Stefan Sleijfer, John W. M. Martens

Summary: This study investigated the mutated genes and mutation patterns, as well as the expression levels of relevant genes, in 101 breast cancer metastatic lesions with ER-positive tumors. The analyses revealed two distinct patient groups, one showing ongoing, active ER and its associated signal route, and the other showing lower ER expression levels. The study highlights the importance of combining mutation and expression analyses to identify patients who may still benefit from anti-hormonal treatment targeting ER.

CANCERS (2023)

Review Cell Biology

Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis

Lissa Wullaert, Jan M. van Rees, John W. M. Martens, Henk M. W. Verheul, Dirk J. Grunhagen, Saskia M. Wilting, Cornelis Verhoef

Summary: This study provides an overview and meta-analysis of the current literature on the value of ctDNA in patients with colorectal liver metastases. The results show a strong association between detectable ctDNA after surgery or completion of adjuvant therapy and oncological outcomes. However, there is no association between detectable ctDNA before surgery and oncological outcomes.
Article Oncology

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival

Noortje Verschoor, Vanja de Weerd, Mai N. Van, Jaco Kraan, Marcel Smid, Joan B. Heijns, Jan C. Drooger, Johanna M. Zuetenhorst, Annemieke van der Padt-pruijsten, Agnes Jager, Stefan Sleijfer, John W. M. Martens, Saskia M. Wilting

Summary: This study demonstrates that mFAST-SeqS can serve as a strong prognostic marker for MBC patients. It is an affordable and easily implementable method for assessing ctDNA levels, offering an alternative tool for prognosis. The aneuploidy score obtained using mFAST-SeqS is significantly correlated with CTC count and is a significant prognostic marker for both PFS and OS in MBC patients.

NPJ BREAST CANCER (2023)

Article Oncology

Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol

D. M. Mens, J. M. van Rees, S. M. Wilting, C. Verhoef

Summary: Chemoradiation therapy (CRT) is the standard of care for treating rectal cancer, but it can cause damage to the surrounding healthy tissue and not all patients benefit from it. This study aims to develop a diagnostic innovation using DNA methylation to predict the effectiveness of CRT for rectal cancer patients.

BMC CANCER (2023)

Article Oncology

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer

Noortje Verschoor, Marcel Smid, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W. M. Martens

Summary: In this study, the researchers investigated the characteristics and therapy resistance of HER2-positive breast cancer through integrating genomics and transcriptomics data. They found that the genomic profiles of primary and metastatic HER2-positive breast cancers were similar, and certain genomic features were predictive of progression-free survival on post-biopsy anti-HER2 treatment. Additionally, a HER2-driven expression profile grouped different types of HER2-positive tumors and indicated the possibility of transformation to ER independence. Integrated genomic and transcriptomic analyses may play a key role in establishing therapeutic options.

BREAST CANCER RESEARCH (2023)

暂无数据